EY
EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
$4.56 +0.00% (+$0.00)
1M -64.96%
Market Cap $384.0M
P/E Ratio -
Div. Yield -
ROE 135.81%
Piotroski F-Score Weak
2/9Valuation
40 /100
Fair P/S 137.68x
P/B 2.31x
P/E N/A
Growth
22 /100
Declining Rev. growth 8.83%
Book val. growth 47.00%
EPS growth N/A
Profitability
17 /100
Weak Gross margin 41.77%
FCF margin 9,726.75%
Net margin 10,994.70%
Quality
0 /100
Poor ROIC 167.81%
Asset turnover 0.01x
ROE 135.81%
Debt
100 /100
Low Debt/Equity 0.13x
Current ratio 4.50x
Int. coverage N/A
Stability
37 /100
Moderate Beta 1.74x
Profitable years 0
Rev. volatility 19.37%
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre EYPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay S. Duker
Employees
214
Headquarters
Watertown
Evenimente viitoare
04 NOV.
Earnings
Upcoming earnings report